Coloplast generated 11% organic growth in the first quarter, reinforcing its position as the world s leading supplier of intimate healthcare products. The company retains the full-year earnings forecast, but lowers its forecast for organic growth exclusively because of weaker revenue flows in the German healthcare business HSC. In DKK-terms, both revenue and earnings will be affected by exchange rate developments. See the full announcement in the enclosed PDF.
Attachments
